Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
Branch KRH, Dagenais GR, Avezum A, Basile J, Conget I, Cushman WC, Jansky P, Lakshmanan M, Lanas F, Leiter LA, Pais P, Pogosova N, Raubenheimer PJ, Ryden L, Shaw JE, Sheu WHH, Temelkova-Kurktschiev T, Bethel MA, Gerstein HC, Chinthanie R, Probstfield JL.
Branch KRH, et al. Among authors: gerstein hc.
Eur J Heart Fail. 2022 Oct;24(10):1805-1812. doi: 10.1002/ejhf.2670. Epub 2022 Sep 20.
Eur J Heart Fail. 2022.
PMID: 36073143
Free article.
Clinical Trial.